Luyan Pharma (002788.SZ) released its performance for the first three quarters, with net profit attributable to shareholders of RMB 212 million, down 3.36% year on year.

Zhitong Finance APP News, Luyan Pharmaceutical (002788.SZ) released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of RMB 16.18 billion, a year-on-year increase of 2.04%; net profit attributable to shareholders of the listed company was RMB 212 million, a year-on-year decrease of 3.36%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB 212 million, a year-on-year decrease of 3.82%; basic earnings per share were RMB 0.55.